Equities

Divi's Laboratories Ltd

DIVISLAB:NSI

Divi's Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)6,000.00
  • Today's Change26.05 / 0.44%
  • Shares traded309.70k
  • 1 Year change+61.94%
  • Beta0.5344
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3,6301,69712,148
Total Receivables, Net23,95020,37225,896
Total Inventory32,64030,34329,159
Prepaid expenses360272271
Other current assets, total36,17040,43416,041
Total current assets96,75093,11783,515
Property, plant & equipment, net55,13049,29247,875
Goodwill, net------
Intangibles, net405375
Long term investments820771720
Note receivable - long term1,280198539
Other long term assets560495562
Total assets154,700144,388133,747
LIABILITIES
Accounts payable8,2407,6257,957
Accrued expenses2,2302,3803,074
Notes payable/short-term debt000
Current portion long-term debt/capital leases10.004.908.20
Other current liabilities, total2,3001,001917
Total current liabilities12,78011,01111,956
Total long term debt202829
Total debt303337
Deferred income tax5,8205,3724,214
Minority interest------
Other liabilities, total370306267
Total liabilities18,99016,71716,465
SHAREHOLDERS EQUITY
Common stock530531531
Additional paid-in capital800799799
Retained earnings (accumulated deficit)134,120126,090115,797
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total260251155
Total equity135,710127,671117,282
Total liabilities & shareholders' equity154,700144,388133,747
Total common shares outstanding265265265
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.